Microorganism producing eicosapentaenoic acid and method for producing eicosapentaenoic acid

US11613728B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11613728-B2
Application numberUS-201917266984-A
CountryUS
Kind codeB2
Filing dateAug 9, 2019
Priority dateAug 10, 2018
Publication dateMar 28, 2023
Grant dateMar 28, 2023

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

An object of the present invention is to provide a microorganism that efficiently produces EPA and a method for producing EPA using the microorganism. The present invention relates to a microorganism having an ability to produce docosahexaenoic acid (DHA), wherein the microorganism contains a protein composed of an amino acid sequence in which at least one of the amino acid residues at positions 6, 65, 230, 231, and 275 in the amino acid sequence represented by SEQ ID NO: 2 has been substituted with another amino acid residue (mutated OrfB), and is capable of producing eicosapentaenoic acid (EPA), and the like.

First claim

Opening claim text (preview).

The invention claimed is: 1. A microorganism having an ability to produce docosahexaenoic acid (DHA), wherein the microorganism contains a mutated OrfB protein composed of an amino acid sequence represented by SEQ ID NO: 2 except for at least one amino acid substitution selected from the group consisting of: N6S, F65L, F230L/N/G/D/A, I231T, and D275G, and wherein the mutated OrfB gives the microorganism ability to produce eicosapentaenoic acid (EPA). 2. A microorganism containing a mutated OrfB protein composed of an amino acid sequence represented by SEQ ID NO: 2 except that at least one amino acid at position 6, 65, 230, 231 or 275 has been substituted with another amino acid. 3. The microorganism according to claim 1 , wherein the microorganism having an ability to produce DHA is a Labyrinthulomycetes microorganism. 4. The microorganism according to claim 3 , wherein the Labyrinthulomycetes microorganism is a Labyrinthulomycetes microorganism belonging to the genus Aurantiochytrium , the genus Thraustochytrium , the genus Ulkenia , the genus Parietichytrium , the genus Labyrinthula , the genus Aplanochytrium , the genus Oblongichytrium , or the genus Schizochytrium. 5. The microorganism according to claim 1 , wherein the microorganism having an ability to produce DHA is a microorganism in which genes encoding respective domains described in the following (a) to (j) having an activity of synthesizing DHA have been introduced into a microorganism that does not have a DHA metabolic pathway: (a) a β-ketoacyl-ACP synthase (hereinafter referred to as KS) domain; (b) a malonyl-CoA:ACP acyltransferase (hereinafter referred to as MAT) domain; (c) an acyl carrier protein (ACP) domain; (d) a ketoreductase (hereinafter referred to as KR) domain; (e) a polyketide synthase dehydratase (hereinafter referred to as PS-DH) domain; (f) a chain elongation factor (hereinafter, referred to as CLF) domain; (g) an acyltransferase (hereinafter referred to as AT) domain; (h) a FabA-like β-hydroxyacyl-ACP dehydratase (hereinafter referred to as FabA-DH) domain; (i) an enoyl-ACP reductase (hereinafter referred to as ER) domain; and (j) a phosphopantetheine transferase (hereinafter referred to as PPT) domain. 6. The microorganism according to claim 5 , wherein the microorganism that does not have a DHA metabolic pathway is a microorganism belonging to the genus Escherichia , the genus Bacillus , the genus Corynebacterium , the genus Yarrowia , the genus Saccharomyces , the genus Candida , or the genus Pichia. 7. A method for producing EPA or an EPA-containing composition, comprising: culturing the microorganism according to claim 1 in a culture medium so as to produce and accumulate EPA or an EPA-containing composition in a culture, and collecting EPA or the EPA-containing composition from the culture. 8. The microorganism according to claim 2 , wherein the microorganism is a Labyrinthulomycetes microorganism. 9. The microorganism according to claim 8 , wherein the Labyrinthulomycetes microorganism is a Labyrinthulomycetes microorganism belonging to the genus Aurantiochytrium , the genus Thraustochytrium , the genus Ulkenia , the genus Parietichytrium , the genus Labyrinthula , the genus Aplanochytrium , the genus Oblongichytrium , or the genus Schizochytrium. 10. The microorganism according to claim 2 , wherein the microorganism does not naturally have a DHA metabolic pathway and has been modified to be able to synthesize DHA by introducing genes encoding domains (a) to (j): (a) a β-ketoacyl-ACP synthase (hereinafter referred to as KS) domain; (b) a malonyl-CoA:ACP acyltransferase (hereinafter referred to as MAT) domain; (c) an acyl carrier protein (ACP) domain; (d) a ketoreductase (hereinafter referred to as KR) domain; (e) a polyketide synthase dehydratase (hereinafter referred to as PS-DH) domain; (f) a chain elongation factor (hereinafter, referred to as CLF) domain; (g) an acyltransferase (hereinafter referred to as AT) domain; (h) a FabA-like β-hydroxyacyl-ACP dehydratase (hereinafter referred to as FabA-DH) domain; (i) an enoyl-ACP reductase (hereinafter referred to as ER) domain; and (j) a phosphopantetheine transferase (hereinafter referred to as PPT) domain. 11. The microorganism according to claim 10 , wherein the microorganism that does not have a DHA metabolic pathway is a microorganism belonging to the genus Escherichia , the genus Bacillus , the genus Corynebacterium , the genus Yarrowia , the genus Saccharomyces , the genus Candida , or the genus Pichia. 12. A method comprising culturing the microorganism according to claim 2 in a culture medium.

Assignees

Inventors

Classifications

  • Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries · CPC title

  • Genes encoding for enzymes or proenzymes · CPC title

  • Protozoa {; Processes using protozoa} · CPC title

  • Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats · CPC title

  • C12N1/105Primary

    Protozoal isolates · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11613728B2 cover?
An object of the present invention is to provide a microorganism that efficiently produces EPA and a method for producing EPA using the microorganism. The present invention relates to a microorganism having an ability to produce docosahexaenoic acid (DHA), wherein the microorganism contains a protein composed of an amino acid sequence in which at least one of the amino acid residues at position…
Who is the assignee on this patent?
Kyowa Hakko Bio Co Ltd
What technology area does this patent fall under?
Primary CPC classification C12N1/105. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).